Recent

% | $
Quotes you view appear here for quick access.

Geron Corporation Message Board

wallstreetwarrior 23 posts  |  Last Activity: May 23, 2016 9:46 AM Member since: Dec 27, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Last year he was over the GERN board telling everyone how smart an investor he was. I wonder how many poor souls he suckered with his free investment advice.

  • wallstreetwarrior by wallstreetwarrior May 21, 2016 1:56 PM Flag

    Like it or not, the BOD and Scarlett will do everything in their power to get the share price into the stratosphere. My reasoning? What would you do? Vote for more dilution so they become worthless? I don't think so!

  • Reply to

    Fed might raise interest rates

    by wereinayellowsubmarine May 19, 2016 4:17 PM
    wallstreetwarrior wallstreetwarrior May 19, 2016 9:22 PM Flag

    I'll bite, what's the word?

  • wallstreetwarrior wallstreetwarrior May 19, 2016 11:14 AM Flag

    Where's mainecoastlover? He's probably bankrupt now!

  • wallstreetwarrior by wallstreetwarrior May 19, 2016 10:13 AM Flag

    Read this;

    nyjets1212 • Apr 19, 2016 2:56 PM
    K 1 Tax Form from Linn ???

    What's this about? Is it legal or a scam? I lost $2,000 last year with Linn after heavy trading with the stock & now my tax person is saying on paper (K1 Tax form), I made $160,000 with Linn & must pay $ 39,000 in taxes!

    Sentiment: Strong Sell
    Sort: Newest | Oldest | Most Replied
    Expand all replies

    tooflessinseattle • 19 hours ago

    nyjets1212, I had the exact same thing happen. Being a Master Limited Partnership, those who invested in the company are liable for the taxes on any profit they made. Somehow these weasels figured out a way to record a profit in 2015 before filing for bankruptcy in 2016. I had to pay taxes on $43,000.00 (line 13 on the K1 Form. I paid 11K in taxes. After that, I sold every MLP that I own in my portfolio as the liabilities from any profits is paid by the shareholders. The president of Linn is the biggest liar EVER. I have heard there are many lawsuits filed against the brokerage firms that recommended this POS company to their clients. If you only lost 2K on the stock, you got out in the nick of time. Less

  • wallstreetwarrior by wallstreetwarrior May 18, 2016 11:10 AM Flag

    Accused Scarlet of trying to keep the share price depressed so he could load up on options at very low price. Anyone else hear that? Scarlet promptly cut him off.

  • 8.2.1 Clinical Development Milestones. For clarity, the provisions of only one of the milestone clauses (a) or (b) of this Section 8.2.1 will apply for any Phase 3 clinical study of a Licensed Product under the Global Development Plan, depending on whether or not Geron has exercised its US Opt-In Rights pursuant to Section 2.2.2 as further provided below. In the event that a combined Phase 2/3 clinical study is conducted in respect of a Licensed Product (irrespective of whether that study is initially established as a combined study or transitions into a combined study once it is under way), where the Phase 2 part of that study satisfies the definition of a “Phase 2” clinical study and the Phase 3 part of that trial satisfies the definition of a “Phase 3” clinical study hereunder, the milestone payment set forth in Section 8.2.1(a) or (b), as applicable, shall be payable upon the first dosing of a Licensed Product in the [*] human subject in the Phase 3 part of such clinical study.

  • Reply to

    Due Diligence - needed

    by zcrazyhorsez May 7, 2016 1:23 PM
    wallstreetwarrior wallstreetwarrior May 7, 2016 3:57 PM Flag

    "In return Janssen and Pharmacyclics will split profits equally and share development and commercialisation costs."
    Geron will receive 20% MOL, of the NET. In the Pharmacyclics agreement, if there is no profit, then they $0.00. In the Geron agreement we will get 20% no matter what the profit is.

  • wallstreetwarrior by wallstreetwarrior May 5, 2016 2:05 PM Flag

    blackmarango
    20019 posts | Last Activity: 4 minutes 27 seconds ago
    Member since: Jan 7, 2006

  • Reply to

    Janssen's Motives

    by blackmarango Apr 25, 2016 1:09 PM
    wallstreetwarrior wallstreetwarrior Apr 25, 2016 1:21 PM Flag

    You're an idiot, Mr Ho.

  • Reply to

    Calling Chippy!

    by blackmarango Mar 29, 2016 10:09 AM
    wallstreetwarrior wallstreetwarrior Mar 29, 2016 11:43 AM Flag

    You need to hold the cans so the string it tight, dummie!

  • Reply to

    SHORTS ARE DEAD!!!! : ^ )

    by joanie_de_1 Mar 20, 2016 11:33 PM
    wallstreetwarrior wallstreetwarrior Mar 21, 2016 12:04 AM Flag

    When GERN hits $10, and it will, the shorts will be out $210,000,000.00. That's a lot of zeros. If it goes to $35, they will lose one billion.

  • wallstreetwarrior wallstreetwarrior Mar 17, 2016 2:16 PM Flag

    He may be Trumps pick for V.P.

  • wallstreetwarrior wallstreetwarrior Mar 16, 2016 11:32 PM Flag

    Maybe you should be standing on a street corner with a billboard. It might be more effective then crying here.

  • wallstreetwarrior wallstreetwarrior Mar 3, 2016 11:27 AM Flag

    AACR

    Presentation
    Session
    Tue, Apr 19, 8:00 AM - 12:00 PM
    2732/20 - Myelosuppression in patients treated with the telomerase inhibitor imetelstat is not mediated through activation of toll-like receptors Gabriela M. Baerlocher1, Joshua Rusbuldt2, Fei Huang2, Jacqueline Bussolari2. 1Inselspital/University Hospital of Bern, CH-3010 Bern, Switzerland; 2Janssen Research & Development, LLC, Spring House, PA Poster Session
    PO.MCB06.02. Cell Cycle Control and Checkpoints
    Tue, Apr 19, 8:00 AM - 12:00 PM
    Tue, Apr 19, 8:00 AM - 12:00 PM
    2731/19 - Impact of hypomethylating agents on hTERT expression and synergistic effect in combination with imetelstat, a telomerase inhibitor, in AML cell lines Joshua Rusbuldt, Jacqueline Bussolari, Aleksandra Rizo, Fei Huang. Janssen Research & Development, LLC, Spring House, PA Poster Session
    PO.MCB06.02. Cell Cycle Control and Checkpoints
    Tue, Apr 19, 8:00 AM - 12:00 PM

    Abstract Number: 2731

    Presentation Title: Impact of hypomethylating agents on hTERT expression and synergistic effect in combination with imetelstat, a telomerase inhibitor, in AML cell lines

    Presentation Time: Tuesday, Apr 19, 2016, 8:00 AM -12:00 PM

    Location: Section 2

  • wallstreetwarrior wallstreetwarrior Mar 2, 2016 2:07 PM Flag

    Once they start, they will come fast and furious.

  • wallstreetwarrior by wallstreetwarrior Mar 2, 2016 1:18 PM Flag

    READ THE SECOND PARAGRAPH CAREFULLY;
    (b) Geron Opt-In. If, and only if, Geron has notified Janssen of Geron’s exercise of US Opt-In Rights prior to the expiration of the Geron Election 8.2.1 Clinical Development Milestones. For clarity, the provisions of only one of the milestone clauses (a) or (b) of this Section 8.2.1 will apply for any Phase 3 clinical study of a Licensed Product under the Global Development Plan, depending on whether or not Geron has exercised its US Opt-In Rights pursuant to Section 2.2.2 as further provided below.

    In the event that a combined Phase 2/3 clinical study is conducted in respect of a Licensed Product (irrespective of whether that study is initially established as a combined study or transitions into a combined study once it is under way), where the Phase 2 part of that study satisfies the definition of a “Phase 2” clinical study and the Phase 3 part of that trial satisfies the definition of a “Phase 3” clinical study hereunder, the milestone payment set forth in Section 8.2.1(a) or (b), as applicable, shall be payable upon the first dosing of a Licensed Product in the [*] human subject in the Phase 3 part of such clinical study.

  • wallstreetwarrior wallstreetwarrior Mar 2, 2016 11:28 AM Flag

    (b) Geron Opt-In. If, and only if, Geron has notified Janssen of Geron’s exercise of US Opt-In Rights prior to the expiration of the Geron Election 8.2.1 Clinical Development Milestones. For clarity, the provisions of only one of the milestone clauses (a) or (b) of this Section 8.2.1 will apply for any Phase 3 clinical study of a Licensed Product under the Global Development Plan, depending on whether or not Geron has exercised its US Opt-In Rights pursuant to Section 2.2.2 as further provided below.

    In the event that a combined Phase 2/3 clinical study is conducted in respect of a Licensed Product (irrespective of whether that study is initially established as a combined study or transitions into a combined study once it is under way), where the Phase 2 part of that study satisfies the definition of a “Phase 2” clinical study and the Phase 3 part of that trial satisfies the definition of a “Phase 3” clinical study hereunder, the milestone payment set forth in Section 8.2.1(a) or (b), as applicable, shall be payable upon the first dosing of a Licensed Product in the [*] human subject in the Phase 3 part of such clinical study.

  • Reply to

    You shorts are fukked and you know it!

    by asiablue123 Feb 13, 2016 8:04 PM
    wallstreetwarrior wallstreetwarrior Mar 2, 2016 10:55 AM Flag

    8.2.1 Clinical Development Milestones. For clarity, the provisions of only one of the milestone clauses (a) or (b) of this Section 8.2.1 will apply for any Phase 3 clinical study of a Licensed Product under the Global Development Plan, depending on whether or not Geron has exercised its US Opt-In Rights pursuant to Section 2.2.2 as further provided below. In the event that a combined Phase 2/3 clinical study is conducted in respect of a Licensed Product (irrespective of whether that study is initially established as a combined study or transitions into a combined study once it is under way), where the Phase 2 part of that study satisfies the definition of a “Phase 2” clinical study and the Phase 3 part of that trial satisfies the definition of a “Phase 3” clinical study hereunder, the milestone payment set forth in Section 8.2.1(a) or (b), as applicable, shall be payable upon the first dosing of a Licensed Product in the [*] human subject in the Phase 3 part of such clinical study.



    (a) Geron Opt-Out. If, and only if, Geron has not notified Janssen of Geron’s exercise of US Opt-In Rights prior to the expiration of the Geron Election Period, each of the following milestone payments shall be due from Janssen to Geron one time only, upon the first achievement of the specified milestone event for a Licensed Product:



    Milestone Event if Geron does not have US Opt-In Rights





    Milestone Payment (US dollars)

    (i) [*]





    [*] ($[*])

    (ii) [*]





    [*] ($[*])

    (iii) [*]





    [*] ($[*])



    (b) Geron Opt-In. If, and only if, Geron has notified Janssen of Geron’s exercise of US Opt-In Rights prior to the expiration of the Geron Election Period, each of the following milestone payments shall be due from Janssen to Geron one time only, upon the first achievement of the specified mile

  • Reply to

    Anyone have an etrade account?

    by wallstreetwarrior Feb 29, 2016 7:00 PM
    wallstreetwarrior wallstreetwarrior Feb 29, 2016 10:56 PM Flag

    Mon Feb 29 17:56:10 2016 Special Margin Maintenance Requirement change

    The margin maintenance requirement for your holding shown below has recently been changed. This may have the effect of increasing or decreasing the purchasing power you have available for trading.

    Account ending in: XXXX-5697
    Holding: GERN (Geron)
    New Requirement: 100%
    Old Requirement: 40%

GERN
2.81-0.13(-4.42%)May 26 4:00 PMEDT